Lupus Efficacy Studies

Let In Vivo Pharmacology Services at JAX perform your lupus-related efficacy study using robust systemic lupus erythematosus (SLE) mouse models.

Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease leading to skin eruptions, joint pain, recurrent pleurisy and kidney disease. JAX offers drug efficacy studies in several common models of SLE: MRL-lpr, NZBWF1 and BXSB.

Efficacy evaluation of lupus compounds

Client studies frequently include characterization of disease pathology and drug response relative to a common SLE therapy, e.g., cyclophosphamide. Pathologic analysis of kidneys, different dosing regimens, or other end points can be tailored to client request. Readouts include creatine and BUN, kidney histopathology, proteinuria, survival, and serum lg.

Lupus models available for studies

MRL/MpJ-Faslpr/J (Stock#  000485)

The most commonly studied mouse model for lupus, MRL-lpr mice, develop an autoimmune disease that reflects pathologies of human SLE. Disease pathologies include lymph node enlargement, increased IgG levels, antinuclear antibody production, proteinuria and kidney failure caused by glomerular inflammation.

NZBWF1/J (Stock# 100008)

NZBWF1/J mice present lupus-like phenotypes such as high levels of antinuclear antibodies, hemolytic anemia, proteinuria and progressive immune complex glomerulonephritis.

BXSB/MpJ (Stock# 000740)

Mice of the BXSB/MpJ strain develop spontaneous lupus-like autoimmune syndrome which is accelerated in males. This model recapitulates the IFN-signature seen in human SLE patients.